---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000054"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:30:06.479342+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Caribou discontinues CAR-NK platform, cuts 12% workforce to extend cash runway into H2 2026

## Summary
- Preliminary cash $311.8M at June 30, 2024; expects to report Q2 results later.
- Discontinues allogeneic CAR-NK preclinical research; focuses on CAR-T cell therapy and four clinical programs.
- Workforce reduction of 21 positions (~12%); expects to complete by end of Q3 2024.
- Estimated severance costs $0.5M–$1.0M in Q3 2024.
- Cash runway extended at least 6 months into H2 2026.

## SEC filing metadata
- accession: 0001619856-24-000054
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/0001619856-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000054
- JSON: https://secwatch.observer/filing/0001619856-24-000054.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.